.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Accenture
Baxter
Fish and Richardson
Chinese Patent Office
McKesson
Covington
Deloitte
Citi
Healthtrust

Generated: December 17, 2017

DrugPatentWatch Database Preview

Betamethasone dipropionate; calcipotriene hydrate - Generic Drug Details

« Back to Dashboard

What are the generic sources for betamethasone dipropionate; calcipotriene hydrate and what is the scope of betamethasone dipropionate; calcipotriene hydrate patent protection?

Betamethasone dipropionate; calcipotriene hydrate
is the generic ingredient in two branded drugs marketed by Perrigo Israel, Tolmar, and Leo Pharma As, and is included in four NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Betamethasone dipropionate; calcipotriene hydrate has eighty-six patent family members in thirty-one countries.

There are sixty-six drug master file entries for betamethasone dipropionate; calcipotriene hydrate. Four suppliers are listed for this compound.

Summary for betamethasone dipropionate; calcipotriene hydrate

Pharmacology for betamethasone dipropionate; calcipotriene hydrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Pharma AsTACLONEXbetamethasone dipropionate; calcipotriene hydrateSUSPENSION;TOPICAL022185-001May 9, 2008RXYesYes► Subscribe► SubscribeY► Subscribe
Leo Pharma AsTACLONEXbetamethasone dipropionate; calcipotriene hydrateSUSPENSION;TOPICAL022185-001May 9, 2008RXYesYes► Subscribe► SubscribeY► Subscribe
Leo Pharma AsTACLONEXbetamethasone dipropionate; calcipotriene hydrateOINTMENT;TOPICAL021852-001Jan 9, 2006ABRXYesYes► Subscribe► Subscribe► Subscribe
TolmarCALCIPOTRIENE AND BETAMETHASONE DIPROPIONATEbetamethasone dipropionate; calcipotriene hydrateOINTMENT;TOPICAL201615-001Jan 14, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Leo Pharma AsTACLONEXbetamethasone dipropionate; calcipotriene hydrateSUSPENSION;TOPICAL022185-001May 9, 2008RXYesYes► Subscribe► Subscribe► Subscribe
Perrigo IsraelCALCIPOTRIENE AND BETAMETHASONE DIPROPIONATEbetamethasone dipropionate; calcipotriene hydrateOINTMENT;TOPICAL200174-001Dec 12, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Leo Pharma AsTACLONEXbetamethasone dipropionate; calcipotriene hydrateOINTMENT;TOPICAL021852-001Jan 9, 2006ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: betamethasone dipropionate; calcipotriene hydrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leo Pharma AsTACLONEXbetamethasone dipropionate; calcipotriene hydrateOINTMENT;TOPICAL021852-001Jan 9, 2006► Subscribe► Subscribe
Leo Pharma AsTACLONEXbetamethasone dipropionate; calcipotriene hydrateSUSPENSION;TOPICAL022185-001May 9, 2008► Subscribe► Subscribe
Leo Pharma AsTACLONEXbetamethasone dipropionate; calcipotriene hydrateOINTMENT;TOPICAL021852-001Jan 9, 2006► Subscribe► Subscribe
Leo Pharma AsTACLONEXbetamethasone dipropionate; calcipotriene hydrateOINTMENT;TOPICAL021852-001Jan 9, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: betamethasone dipropionate; calcipotriene hydrate

Country Document Number Estimated Expiration
New Zealand515142► Subscribe
Portugal2450043► Subscribe
Japan2013075924► Subscribe
Slovenia1331927► Subscribe
Norway20015175► Subscribe
Japan5699169► Subscribe
Hungary230005► Subscribe
Japan2004512297► Subscribe
Japan2002542293► Subscribe
Hungary0200879► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Medtronic
Healthtrust
Queensland Health
US Army
Citi
Baxter
Cipla
QuintilesIMS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot